Elizabeth Haase, MD, former chair of the American Psychiatric Association's Committee on Climate Change, shared her advice ...

Spravat (esketamine) FastTrack Program by Ketamine Academy Live, step-by-step program to help clinics get certified, operational, and reimbursed for Spravato®-without the usual delays or confusion.

Methods and analysis This is a protocol for a randomised, double-blinded, placebo-controlled clinical trial to evaluate the effect of esketamine on PSD in patients undergoing spinal surgery. Patients ...

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

Esketamine, a derivative of ketamine, is a rapid-acting antidepressant. Previously, it was approved in combination with oral antidepressants for individuals with treatment-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

However, and importantly, the novel contribution of our study will be that we will pay special attention to specific surgery (ie, thoracotomy) and specific drug (ie, esketamine), and dig into both the ...

Esketamine hydrochloride is a vital drug to be used for treating mental illness. "This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where ...

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" by Kristen Monaco ...